Carboxyamidotriazole

PharmaPoint: Glaucoma Global Drug Forecast and Market Analysis to 2026 Summary Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure IOP is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 3050%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease. Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues PGAs are generally used as a firstline treatment, with beta blockers BBs, alpha adrenergic receptor agonists AAs, and carbonic anhydrase inhibitors CAIs also frequently used, albeit generally as secondline therapies in combination with PGAs. Certain combinations of available drugs are marketed as part of fixeddose combination FDC therapies. Cholinergic agonists, also known as miotics, can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, and CAIs. Scope Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. Topline Glaucoma market revenue from 20162026. Annual cost of therapy ACOT and major pipeline product sales in this forecast period are included. Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting glaucoma therapeutics sales in the 7MM. Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative earlystage projects, and detailed analysis of latestage pipeline products. Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the glaucoma therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.